Micronutrient Status Involved in Immunity in Elderly Patients With COVID-19

Covid19 Clinical Trial

— MicroCovAging  

Official title:

Micronutrient Status Involved in Immunity in Elderly Patients With COVID-19

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04877509
• Other study ID #: 69HCL20_0730 A067
• Status: Completed
• Start date: March 1, 2020
• Est. completion date: May 1, 2021

Study information

• Verified date: March 2021
• Source: Hospices Civils de Lyon
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

During the ongoing COVID-19 pandemic, age was clearly the major factor of mortality. Increasing age was strongly associated with this risk, with the upper 80 years age group having more than 12-fold increased risk compared with those aged 50-59 years. Male gender was also associated with a doubling of risk.

The elderly subject is particularly exposed to global denutrition with risk of micronutrients deficiencies such as vitamins and trace elements. Those deficits expose to lower immunity. In addition, viral infection as COVID-19 can also worsen these deficits.

In general, low levels or intakes of micronutrients such as Zn, Se and vitamin A have been associated with adverse clinical outcomes during viral infections. This notion has been confirmed in a recent review proposing that besides vitamins A and D also B vitamins, vitamin C, omega-3 polyunsaturated fatty acids, as well as selenium, zinc and iron should be considered in the assessment of micronutrients in COVID-19 patients.

In this context, the MicroCovAging study will evaluate copper, zinc and selenium, vitamin A, D and E status in elderly subjects affected by COVID- 19 and to correlate this status with prognosis of this disease.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 229
• Est. completion date: May 1, 2021
• Est. primary completion date: December 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

• Hospitalized adult patient = 50 years at the time of admission,

• Suffering from confirmed COVID-19 (positive quantitative PCR for SARS-CoV-2 and/or chest scanner suggestive of COVID-19),

• Informed and non-opposed to the research. Patient will be informed of the study by his medical doctor during hospitalization or by post thanks to a generic information sheet dedicated to COVID-19 researches.

Exclusion Criteria:

• Adult patient < 50 years at the time of admission

• Negative quantitative PCR for SARS-Cov-2

Related Conditions & MeSH terms

• Covid19

Intervention

Biological:
• Selenium, Zinc and Copper, Vitamin A, D, E plasma concentrations during patient hospitalization
Micronutrient assays on heparinized plasma.

Locations

Country	Name	City	State
France	Chls Cbap	Pierre-Bénite

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Selenium, Zinc and Copper, Vitamin A, D and E plasma concentrations of 229 over 50 year's patients hospitalized suffering from COVID-19.		Up to 3 months

External Links

•   Related Info